XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating Expenses:        
Research and development $ 3,239 $ 4,329 $ 6,517 $ 9,405
General and administrative 3,481 2,818 6,823 5,828
Total operating expenses 6,720 7,147 13,340 15,233
Operating loss (6,720) (7,147) (13,340) (15,233)
Other income (expense):        
Investment income, net 94 47 158 70
Other expense, net 0 (90) (149) (90)
Total other income (expense) 94 (43) 9 (20)
Net loss before benefit from income taxes and noncontrolling interests (6,626) (7,190) (13,331) (15,253)
Benefit from income taxes 0 (1,508) (2,479) (1,508)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders $ (6,626) $ (5,682) $ (10,852) $ (13,745)
Basic and diluted loss per share        
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share) $ (0.11) $ (0.10) $ (0.18) $ (0.27)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share) $ (0.11) $ (0.10) $ (0.18) $ (0.27)
Weighted average common shares outstanding        
Basic shares 60,533 59,510 60,546 50,862
Diluted shares 60,533 59,510 60,546 50,862